tirzepatide injection site irritation Red and Itchy: Causes and Solutions What should I do if

placebo INDIANAPOLIS, May 21, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRIUMPH-1, a Phase 3 clinical trial evaluating the efficacy and safety of retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, in adults with obesity or overweight and at least one weight-related comorbidity and without diabetes

Reduced Appetite Guidance Nutrient-dense meal plans that ensure you're getting everything your body needs, even when you're not hungry

In our study, CT26 tumor-bearing mice exhibited weight loss and significantly elevated serum IL-6 and IL-1 levels

Adequate magnesium intake (300400 mg daily for adults) supports cardiovascular function and glucose metabolism, both relevant to weight loss success